Literature DB >> 28024691

Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.

Irina Demidova1, Viacheslav Grinevich2, Ashot Avdalian3, Evgeny Imyanitov4, Marina Gikalo5, Nikita Savelov5, Inna Novikova6, Olga Samuilenkova3, Vladislav Tiurin4, Elena Ulianova6, Ilya Tsimafeyeu7, Sergey Tjulandin7.   

Abstract

BACKGROUND: Clinical guidelines highly recommended the detection of potentially targetable genetic aberrations such as anaplastic lymphoma kinase (ALK) rearrangements in patients with non-small cell lung cancer (NSCLC). Few methods, such as the ALK break apart FISH assay and IHC for ALK protein, are approved for routine diagnostics. However, some challenges exist in selecting the most reliable, robust and cost-effective algorithm, especially for large-scale screening of NSCLC patients.
MATERIALS AND METHODS: A total of 4002 FFPE samples from Russian patients with NSCLC were tested for ALK rearrangement using two algorithms: FISH testing only (2334 samples) and IHC screening supported by FISH in positive or equivocal cases (1546 samples). Cross validation of the methods was performed blindly in 122 specimens. All discrepant IHC/FISH cases were examined for unbalanced 5'/3'-end ALK expression and variant-specific RT PCR.
RESULTS: The sensitivity and specificity of IHC compared to FISH was 100% and 99%, respectively, therefore initial IHC screening was strongly supported. The prevalence of ALK rearrangements was estimated to be 7.8% and 6.6% for the FISH and IHC/FISH groups, respectively, with significant correlations for female gender, non-smoking status and age below 60. The use of FISH after IHC screening revealed 10 additional positive cases among equivocal samples (13.4%). Seven IHC/FISH cases (0.5% of the total group) characterized as discordant were reevaluated, and four were reclassified as truly discrepant. The PCR-based investigation revealed chimeric transcripts in IHC-/FISH+ and IHC+/FISH borderline samples, while no transcript was found in two IHC+/FISH- cases.
CONCLUSION: These results reveal the utility of the two-step testing algorithm for the evaluation of potentially complicated cases with preanalytic defects, providing additional information for IHC equivocal cases without a significant increase in cost. The evaluation of discrepant cases appears to be necessary to better understand ALK biology and should be included in the routine testing algorithm.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ALK-testing; FISH; Immunohistochemistry; Non-small cell lung cancer; Optimal algorithm for ALK testing

Mesh:

Substances:

Year:  2016        PMID: 28024691     DOI: 10.1016/j.lungcan.2016.11.001

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

1.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Authors:  Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

Review 2.  Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets.

Authors:  Mercedes L Dalurzo; Alejandro Avilés-Salas; Fernando Augusto Soares; Yingyong Hou; Yuan Li; Anna Stroganova; Büge Öz; Arif Abdillah; Hui Wan; Yoon-La Choi
Journal:  Onco Targets Ther       Date:  2021-09-01       Impact factor: 4.345

3.  Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study.

Authors:  Ilya Tsimafeyeu; Fedor Moiseenko; Sergei Orlov; Elena Filippova; Alexander Belonogov; Aleksey Nebesnykh; Amir Khalimov; Elena Karabina; Valentina Shikina; Ahmed Abdelgafur; Galina Statsenko; Irina Titova; Dmitry Isaichikov; Galina Makarnyaeva; Aleksey Mordovskiy; Oksana Barkovskaya; Aleksey Smirnov; Marina Gikalo; Nikita Savelov; Dmitry Kosov; Evgeny Imyanitov; Irina Demidova; Sergei Tjulandin
Journal:  J Glob Oncol       Date:  2019-05

4.  Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.

Authors:  Julie A Vendrell; Sylvie Taviaux; Benoît Béganton; Sylvain Godreuil; Patricia Audran; David Grand; Estelle Clermont; Isabelle Serre; Vanessa Szablewski; Peter Coopman; Julien Mazières; Valérie Costes; Jean-Louis Pujol; Pierre Brousset; Isabelle Rouquette; Jérôme Solassol
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.379

5.  Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?

Authors:  Gaëlle Tachon; Ulrich Cortes; Sophie Richard; Sébastien Martin; Serge Milin; Camille Evrard; Corinne Lamour; Lucie Karayan-Tapon
Journal:  Cancer Med       Date:  2019-10-25       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.